



4 March 2024

## **ASX ANNOUNCEMENT**

### **Change of registered office**

Control Bionics Ltd (ASX: CBL) advises that as from 8 March 2024, its registered office is as follows:

Level 4  
11 Pearson Street  
Cremorne VIC 3121

This announcement was authorised by CBL CEO, Jeremy Steele.

#### **About Control Bionics:**

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by diseases such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS). Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts like the mouse button. Control Bionics offers the only such product to harness three modalities — touch, eye and NeuroNode control — which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

In October 2023 Control Bionics announced the launch of its next generation NeuroNode device, the NeuroStrip. The ultra-lightweight device features a direct-to-skin electrode which has comprehensive physiological telemetry and is a material advancement on the NeuroNode. NeuroStrip has a range of potential new applications in disability, medtech, and consumer markets.

Control Bionics operates in North America, Australia, Singapore, and Japan.